{"id":4366,"date":"2026-11-17T09:00:00","date_gmt":"2026-11-17T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4366"},"modified":"2026-11-17T20:44:38","modified_gmt":"2026-11-18T00:44:38","slug":"ebmt-study-links-graft-source-to-mf-engraftment","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4366","title":{"rendered":"EBMT Study Links Graft Source to MF Engraftment"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_EBMT_Myelofibrosis_Transplant_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4377\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_EBMT_Myelofibrosis_Transplant_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_EBMT_Myelofibrosis_Transplant_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_EBMT_Myelofibrosis_Transplant_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_EBMT_Myelofibrosis_Transplant_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261117_EBMT_Myelofibrosis_Transplant_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>EBMT (registry study)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed registry analysis (Bone Marrow Transplantation)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Haploidentical hematopoietic cell transplant<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Graft source and CD34+ dose<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Engraftment<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Myelofibrosis<\/p>\n<h4>Summary<\/h4>\n<p>An EBMT registry analysis of 263 myelofibrosis patients undergoing haploidentical HCT reported primary graft failure in 12% of marrow versus 4% of peripheral-blood graft recipients. Higher peripheral-blood CD34+ dose correlated with faster neutrophil recovery, but four-year survival did not differ significantly by source.<\/p>\n<p>The peer-reviewed Bone Marrow Transplantation article appeared online November 17, ahead of issue assignment. The study reviewed transplants from 2012\u20132020, with 163 peripheral-blood and 100 marrow grafts. In peripheral-blood recipients, a threshold of at least 7\u00d710^6 CD34+ cells\/kg associated with day-28 engraftment of 83% versus 65%; the groups differed at baseline and by era.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> peripheral-blood collection and higher stem-cell dose may reduce early graft failure in MF, a disease with fibrotic marrow and difficult engraftment.<\/p>\n<p><strong>Interpretation B:<\/strong> selection, conditioning, prior splenectomy and calendar-era differences could explain the association. This nonrandomized registry result cannot prove graft choice causes better engraftment, and no long-term survival gain was shown. Chronic GVHD and quality-of-life tradeoffs must be weighed against faster early recovery; the abstract does not resolve them.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Myelofibrosis is a clonal myeloproliferative neoplasm with marrow fibrosis and extramedullary hematopoiesis. Haploidentical HCT replaces diseased hematopoiesis with donor HSCs after conditioning; graft source and CD34+ dose affect early repopulation.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Peer-reviewed online abstract verified.<\/li>\n<li>Missing: full adjusted hazard models, donor characteristics, chronic GVHD and center effects.<\/li>\n<li>Upgrade: prospectively adjusted multicenter replication.<\/li>\n<li>Downgrade: attenuation after confounder control.<\/li>\n<li>Falsify a survival claim if longer follow-up remains neutral.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The paper supports renewed examination of source and dose in MF haplo-HCT protocols, not a categorical graft-source rule.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: mixed. Confidence in Facts: Moderate. Confidence in Interpretation: Low to Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An EBMT registry analysis of 263 myelofibrosis patients undergoing haploidentical HCT reported primary graft failure in 12% of marrow versus 4% of peripheral-blood graft recipients. Higher peripheral-blood CD34+ dose correlated with faster neutrophil recovery,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4377,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1479,1517,60],"class_list":["post-4366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-ebmt","tag-haploidentical-transplant","tag-myelofibrosis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4366"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4366\/revisions"}],"predecessor-version":[{"id":4382,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4366\/revisions\/4382"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4377"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}